Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript

Greco, Marianna; Caocci, Giovanni; La Nasa, Giorgio
January 2013
Case Reports in Hematology;2013, p1
Academic Journal
Chronic myeloid leukemia (CML) with the rare fusion gene e19a2, encoding a p230 protein, has been described in patients with typical or rather aggressive clinical course. Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minority of p230 positive patients have been treated with TKIs. We report two cases of CML patients carrying the p230 transcript, who achieved fast and deep complete molecular response (CMR) after frontline treatment with nilotinib. Our results suggest the use of nilotinib as frontline agent for the treatment of this CML variant.


Related Articles

  • CD117 (c-kit) Expression on CD34+ Cells Participates in the Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia in the First Chronic Phase. Dybko, Jaroslaw; Haus, Olga; Jaźwiec, Bożena; Urbaniak, Joanna; Woźniak, Mieczysław; Kaczmar-Dybko, agnieszka; Urbaniak-Kujda, Donata; Kapelko-Slowik, Katarzyna; Kuliczkowski, Kazimierz // Acta Haematologica;Aug2014, Vol. 132 Issue 2, p166 

    Background: Chronic myeloid leukemia (CML) biology seemed to be perfectly explored especially at the beginning of the tyrosine kinase inhibitors era. Later years with imatinib and second-generation tyrosine kinase inhibitors showed a variety of resistance mechanisms and it became obvious that...

  • Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses. Jiye, A.; Sixuan Qian; Guangji Wang; Bei Yan; Sujiang Zhang; Qing Huang; Lingna Ni; Weibin Zha; Linsheng Liu; Bei Cao; Ming Hong; Hanxin Wu; Hua Lu; Jian Shi; Mengjie Li; Jianyong Li // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure. Metabonomic and genomic profiling of patients' responses to drug interventions can provide...

  • Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study. Dahlén, Torsten; Edgren, Gustaf; Lambe, Mats; Höglund, Martin; Björkholm, Magnus; Sandin, Fredrik; Själander, Anders; Richter, Johan; Olsson-Strömberg, Ulla; Ohm, Lotta; Bäck, Magnus; Stenke, Leif; Swedish CML Group and the Swedish CML Register Group // Annals of Internal Medicine;8/2/2016, Vol. 165 Issue 3, p161 

    Background: Tyrosine kinase inhibitors (TKIs) have increased survival dramatically for patients with chronic myeloid leukemia (CML), but continuous administration of these drugs may elicit long-term toxicity.Objective: To investigate the incidence of vascular events in...

  • Atypical Chronic Myeloid Leukaemia with CD117-Positive Blast Cells Treated with Imatinib: A Report of Two Cases. Breccia, Massimo; Russo, Eleonora; De Propris, Maria Stefania; Frustaci, Annamaria; Alimena, Giuliana // Acta Haematologica;Oct2006, Vol. 116 Issue 3, p211 

    The article describes two cases of chronic myeloid leukemia (CML) treated with imatinib mesylate on the basis of the bright expression of c-kit on blast cells. The first case involves a 53-year-old woman who was admitted to a hospital due to itchiness and splenomegaly. The second case involves a...

  • Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Oyekunle, Anthony; Klyuchnikov, Evgeny; Ocheni, Sunday; Kröger, Nicolaus; Zander, Axel R.; Baccarani, Michele; Bacher, Ulrike // Acta Haematologica;2011, Vol. 126 Issue 1, p30 

    Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic...

  • Switching-On Adherence in Chronic Myeloid Leukemia. Leader, Avi; Raanani, Pia // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p138 

    The authors reflect on the clinical challenge in the management of chronic myeloid leukemia (CML) due to patients' nonadherence to tyrosine kinase inhibitors (TKI). They cite the retrospective study by Maeda et al. that suggests that switching medications from imatinib to nilotinib may resolve...

  • Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors. Maeda, Yasuhiro; Okamoto, Atsushi; Kawaguchi, Shin-ichiro; Konishi, Akiko; Yamamoto, Kenta; Eguchi, Go; Kanai, Yoshitaka; Yamaguchi, Terufumi // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p140 

    The article discusses the improved drug adherence in patients with chronic myeloid leukemia (CML) by switching to second-generation tyrosine kinase inhibitors (TKI). It compared the drug adherence rates from Imatinib (IM) to TKI nilotinib (NILO). It notes that adherence is a critical factor for...

  • Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Santoleri, Fiorenzo; Lasala, Ruggero; Ranucci, Elena; La Barba, Gaetano; Di Lorenzo, Roberto; Vetrò, antonio; Di Bartolomeo, Paolo; Costantini, alberto // Acta Haematologica;Jun2016, Vol. 136 Issue 1, p45 

    Objective: Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence...

  • Highlights from EHA 2013.  // Personalized Medicine in Oncology;Nov2013, Vol. 2 Issue 7, p389 

    The article discusses information from the European Hematology Association (EHA) 2013 congress. The adenosine triphosphate analog imatinib selectively inhibits the enhanced tyrosine activity of the fusion gene BCR-ABL1 oncoprotein. The second-generation oral tyrosine kinase inibitor (TKI)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics